DLA Piper advises Pfizer on $635 million acquisition from Baxter
DLA Piper has advised Pfizer on the US$635 million acquisition of commercial vaccines from Baxter, with the transaction closing successfully on 1 December 2014.
The deal included the meningitis prevention vaccine NeisVac-C and the well-known vaccine FSME-IMMUN/Ticovac. Furthermore, Pfizer acquired the production facility in Austria, where the two vaccines are manufactured.
The transaction was led by DLA Piper partners Christoph Mager and Elisabeth Stichmann, who also advised Pfizer already during the structuring of the acquisition.